1-(4-吡啶基)哌嗪 → Methyl 4-[2-[4-(4-pyridyl)piperazin-1-yl]acetyl]phenylacetate

HRID 2204

反应方程式

HRID 2204 反应方程式
Cl[CH2:2][C:3]([C:5]1[CH:10]=[CH:9][C:8]([CH2:11][C:12]([O:14][CH3:15])=[O:13])=[CH:7][CH:6]=1)=[O:4].[N:16]1[CH:21]=[CH:20][C:19]([N:22]2[CH2:27][CH2:26][NH:25][CH2:24][CH2:23]2)=[CH:18][CH:17]=1>C(#N)C>[N:16]1[CH:21]=[CH:20][C:19]([N:22]2[CH2:23][CH2:24][N:25]([CH2:2][C:3]([C:5]3[CH:10]=[CH:9][C:8]([CH2:11][C:12]([O:14][CH3:15])=[O:13])=[CH:7][CH:6]=3)=[O:4])[CH2:26][CH2:27]2)=[CH:18][CH:17]=1

参与物

4

反应物 2

HCID 705171-(4-吡啶基)哌嗪HCID 11128026Benzeneacetic acid, 4-(chloroacetyl)-, methyl ester

产物 1

HCID 18918371Methyl 4-[2-[4-(4-pyridyl)piperazin-1-yl]acetyl]phenylacetate

试剂、催化剂与溶剂 1

HCID 6342乙腈溶剂2 次

实验过程

A solution of methyl 4-chloroacetylphenylacetate (260 mg) in acetonitrile (4 ml) was added dropwise over 15 minutes to a stirred solution of 1-(4-pyridyl)piperazine (375 mg) in acetonitrile (10 ml) and the mixture stirred overnight. The supernatent was decanted from the solid formed, concentrated in vacuo and purified by flash chromatography on neutral alumina, eluting with dichloromethane then 0.25% v/v methanol/dichloromethane and finally 0.5% v/v methanol dichloromethane. Concentration of the fractions in vacuo gave the title compound, 96 mg, as a white crystalline solid: m.p. 127°-129° C.; NMR (d6 DMSO) δ 8.15(2H,d), 7.98(2H,d), 7.41(2H,d), 6.81(2H,d), 3.91(2H,s), 3.78(2H,s), 3.53(3H,s), 3.33(4H,t), 2.64(4H,t); m/e 354(M+H )+ ; calculated for C20H23N3O3 : C, 68.0; H, 6.6; N, 11.9. found: C, 68.2; H, 6.6; N, 11.9%.

后处理

  1. customThe supernatent was decanted from the solid
  2. customformed
  3. concentrationconcentrated in vacuo
  4. custompurified by flash chromatography on neutral alumina
  5. washeluting with dichloromethane

来源与证据

ORD记录
ord-dec26e4a500a423b998283ba15ea943b
来源数据集
uspto-grants-1998_03
专利号
US05728701

关联笔记

加载中…